In Vitro Immunogenicity Assessments

Integrating in vitro immunogenicity analyses into the preclinical strategy is essential for thorough validation and regulatory compliance. While in silico tools offer initial insights, in vitro assays are necessary to confirm findings and address immunogenicity concerns. EpiVax provides comprehensive in vitro immunogenicity screening services, developed and perfected over 25 years. Our skilled research associates and state-of-the-art lab produce valuable data to guide therapeutic and vaccine screening and optimization. EpiVax excels in both cell-based and cell-free assays, offering high-quality, actionable data and expert recommendations tailored to each biologic therapy. Our assays effectively monitor HLA binding and T cell activation, supporting informed decisions from the preclinical stages to commercialization and supporting regulatory filings.